The present study provides evidence of benefit for ILK treatment on the progression of heart failure caused by doxorubicin-induced cardiomyopathy, a non-ischemic cardiomyopathy whose pathophysiological features closely resemble those of dilated cardiomyopathy in humans. This evidence concerns the gene ILK and cardiomyopathy.